watch the full video Play Full Video

A Clot Retriever Device for the Treatment of Acute Ischemic Stroke and Occlusions in Peripheral Vessels

A Clot Retriever Device for the Treatment of Acute Ischemic Stroke and Occlusions in Peripheral Vessels

CLOT-SPECIFIC

CLOT-SPECIFIC

Micro-surface technology designed for a robust engagement with the clot's micro-structure

GENTLE AND SAFE

GENTLE AND SAFE

Polymer-based, non-traumatic to the vessel wall

FAST AND SIMPLE

FAST AND SIMPLE

“Over-the-Wire” technology designed for a first pass revascularization

Background

Stroke

  • Stroke is the third-leading cause of death in the U.S., Canada, Europe, and Japan1
  • The NIH estimates that stroke costs exceed $73 billion in U.S. healthcare expenditure per year1
  • In the U.S. there are 795,000 new or recurrent strokes each year2
over $1 billion

Estimated potential global market size of clot retriever devices for ischemic stroke4:

over $1 billion

Periphery

    Thrombectomy procedures are being used in cases of3:

  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Arterio-Venous Fistulas for hemodialysis
  • Arterial Emboli
  • Acute Myocardial Infarction
1$825 million

The global market size of peripheral - thrombectomy devices in 20165:

$825 million

(Peripheral vascular: $210 million; Cardiovascular: $615 million)

About

Triticum is developing a new generation clot retriever device for the treatment of acute ischemic stroke and occlusions in peripheral vessels

  • The Triticum architecture is inspired by biological concepts
  • Made of soft polymer, using micro-surfaces technology to engage with the clot's micro-structure
  • This results in a robust but yet gentle and safe retrieval of the blood clot

Team

Close

Doron Ben Ami, MHA

Founder and Managing Director

David Blossom, MJ

Advisory Board Member

Seasoned executive with more than 20 years of management experience holding various leadership roles. Among them Associate Vice President, Eastern Europe and Israel region at Merck, Managing Director of the Merck’s subsidiary in Israel and the General Manager of Lundbeck, Israel. Serves as a consultant for commercial and business development to Pharma and Medical Device companies.

Udi Sadeh, MD

Medical Director

Udi Sadeh, MD

Medical Director

Doron Ben Ami, MHA

Founder and Managing Director

Head of the Intervention Neuro-Radiology Stroke Service, Imaging Division, Sourasky Medical Center, Tel Aviv, Israel. A former pilot in the Israeli Air Force.

David F. Kallmes, MD

Scientific Advisor

David F. Kallmes, MD

Scientific Advisor

Udi Sadeh, MD

Medical Director

Intervention Neuro-Radiology specialist at Mayo Clinic in Rochester, Minnesota, USA. Head of the Applied Neuroradiology Laboratory that conducts multiple preclinical research and clinical trials for stroke and other related conditions. Working on establishing, developing and validating techniques and devices testing within the Intervention Neuro-Radiology field.

Oded Shoseyov, PhD

Scientific Advisor

Oded Shoseyov, PhD

Scientific Advisor

David F. Kallmes, MD

Scientific Advisor

A member of the Nano Science and Nano Technology Center at the Hebrew University of Jerusalem. He has extensive experience in Bio-Inspired Nanocomposite materials, has more than 160 publications and 50 patents and is the scientific founder of 10 biotech companies.

Ascher Shmulewitz, MD, PhD

Advisory Board Member

Ascher Shmulewitz, MD, PhD

Advisory Board Member

Oded Shoseyov, PhD

Scientific Advisor

Prolific inventor and serial entrepreneur in biomedical technologies. Has originated over two dozen life science companies and has led 14 of these companies to successful exits, mostly through M&A transactions with large medical device companies.

David Blossom, MJ

Advisory Board Member

David Blossom, MJ

Advisory Board Member

Ascher Shmulewitz, MD, PhD

Advisory Board Member

Seasoned sales and marketing executive with more than 25 years of medical device experience. Worked with several prestigious medical device companies among them Boston Scientific Corporation, Covidien/Aspect Medical Systems, Cappella Medical Systems and InspireMD.

Doron Ben Ami, MHA

Founder and Managing Director